Flexion Therapeutics (FLXN)
US Market

Flexion Therapeutics Stock Analysis & Ratings

FLXN Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$4.30 - $13.66
Previous Close$9.12
Average Volume (3M)1.77M
Market Cap$458.93M
Enterprise ValueN/A
P/E Ratio-4.6
Next EarningsN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score4

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Flexion Therapeutics’s price range in the past 12 months?
Flexion Therapeutics lowest stock price was $4.30 and its highest was $13.66 in the past 12 months.
    What is Flexion Therapeutics’s market cap?
    Flexion Therapeutics’s market cap is $458.93M.
      What is Flexion Therapeutics’s price target?
      The average price target for Flexion Therapeutics is $10.67. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $12.00 ,the lowest forecast is $10.00. The average price target represents 17.00% Increase from the current price of $9.12.
        What do analysts say about Flexion Therapeutics?
        Flexion Therapeutics’s analyst rating consensus is a ‘Hold. This is based on the ratings of 6 Wall Streets Analysts.
          When is Flexion Therapeutics’s upcoming earnings report date?
          The company’s upcoming earnings report date is not yet available.
          How were Flexion Therapeutics’s earnings last quarter?
          Currently, no data Available
          Is Flexion Therapeutics overvalued?
          According to Wall Street analysts Flexion Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Flexion Therapeutics pay dividends?
            Flexion Therapeutics does not currently pay dividends.
            What is Flexion Therapeutics’s EPS estimate?
            Flexion Therapeutics’s EPS estimate is -$1.98.
              How many shares outstanding does Flexion Therapeutics have?
              Flexion Therapeutics has 50,320,000 shares outstanding.
                What happened to Flexion Therapeutics’s price movement after its last earnings report?
                Currently, no data Available
                Which hedge fund is a major shareholder of Flexion Therapeutics?
                Among the largest hedge funds holding Flexion Therapeutics’s share is First Eagle Investment Management LLC. It holds Flexion Therapeutics’s shares valued at 237K.


                  Flexion Therapeutics Stock Analysis

                  Smart Score
                  Price Target
                  ▲(17.00% Upside)
                  The Flexion Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Flexion Therapeutics

                  Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand. The company was founded by Michael D. Clayman and Neil Bodick in 2007 and is headquartered in Burlington, MA.

                  Similar Stocks
                  Price & Change
                  Ampio Pharmaceuticals
                  Radius Health
                  Axsome Therapeutics

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis